Laurus Labs Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 24 Jul 2026

Company page: Laurus Labs share price, financials & guidance record

Laurus Labs reported robust Q1 FY27 results, achieving record quarterly revenue of ₹2,026 crores, a 29% YoY increase, and strong EBITDA margin expansion to 31.8%. This performance was fueled by a 69% growth in the CDMO segment and a 10% rise in Affordable Medicine revenue. The company continues its aggressive investment in capacity and new modalities, leading to a slight increase in net debt, while maintaining a positive outlook for sustained growth and value creation.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 22.6%, net profit up 83.5% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	1,185	1,265	1,650	1,433	1,567 +32%	1,509 +19%	1,580 −4%	1,757 +23%
Expenses	1,003	1,059	1,255	1,105	1,177	1,164	1,205	1,258
EBITDA	182	206	395	327	390 +114%	346 +68%	375 −5%	499 +53%
Margin	15%	16%	24%	23%	25%	23%	24%	28%
Other income	12	7	72	22	28	14	13	20
Interest	45	48	49	44	34	31	34	35
Depreciation	91	89	88	94	96	94	95	96
Profit before tax	58	77	330	211	289 +398%	234 +204%	259 −22%	388 +84%
Tax rate	27%	25%	24%	25%	25%	25%	26%	25%
Net profit	42	57	252	158	216 +414%	175 +207%	192 −24%	290 +84%
EPS	0.79	1.06	4.67	2.93	4.00	3.24	3.55	5.37

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls